Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NBI-1076986 by Neurocrine Biosciences for Movement Disorders: Likelihood of Approval
NBI-1076986 is under clinical development by Neurocrine Biosciences and currently in Phase I for Movement Disorders. According to GlobalData, Phase...